Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Research Article

Effects of COVID-19 Pandemic on Pulmonary Tuberculosis (TB) Occurrence in the South of Iran

Author(s): Reza Faryabi, Ali Kamali, Rasoul Raesi, Kiavash Hushmandi, Seyed Saeed Tabatabaee, Hedyeh Askarpour, Shohreh Alian Samakkhah and Salman Daneshi*

Volume 21, Issue 3, 2025

Published on: 02 January, 2025

Page: [267 - 275] Pages: 9

DOI: 10.2174/011573398X318641240914123736

Price: $65

Abstract

Background and Objective: Tuberculosis (TB) was one of the most challenging diseases in terms of diagnosis, treatment, and control during the COVID-19 pandemic. The present study was conducted to investigate the impact of the COVID-19 pandemic on the incidence of tuberculosis.

Materials and Methods: This study was cross-sectional, based on a census of all patients with tuberculosis whose information was available in the tuberculosis registration system of the Health Vice-Chancellor of Jiroft University of Medical Sciences from 2016 to 2021. In this study, demographic information and variables related to the type of tuberculosis, disease case, treatment result, and treatment regimen were collected using a researcher-made questionnaire.

Results: The incidence of tuberculosis during the COVID-19 pandemic was significantly reduced by 57% compared to the pre-pandemic period. There was no significant difference between the pre-COVID-19 era and the pandemic era in terms of demographic variables and several determining factors in TB patients.

Conclusion: The COVID-19 pandemic was found to impact the control of the tuberculosis program. Delays in referral, diagnosis, and treatment led to an increase in the spread of tuberculosis, particularly within households, an increase in the number of deaths, and an increase in drug resistance of the tuberculosis microbe. Therefore, it is recommended that awareness programs for the public about tuberculosis be organized and that more education be provided to health and treatment staff about tuberculosis to ensure that the control measures implemented in recent decades are not wasted.

Keywords: Tuberculosis (TB), COVID-19 pandemic, acute respiratory syndrome, infectious diseases, awareness programs, tuberculosis microbe.

[1]
Worobey M, Levy JI, Malpica Serrano L, et al. The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic. Science 2022; 377(6609): 951-9.
[http://dx.doi.org/10.1126/science.abp8715] [PMID: 35881010]
[2]
Raesi R, Abbasi Z, Raei M, Hushmandi K. The relationship between the incidence of COVID-19 with the underlying diseases in hospitalized patients. EBNESINA 2022; 24(3): 75-80.
[3]
Yu B, Chen X, Rich S, Mo Q, Yan H, Yan H. Dynamics of the coronavirus disease 2019 (COVID-19) epidemic in Wuhan City, Hubei Province and China: A second derivative analysis of the cumulative daily diagnosed cases during the first 85 days. Global Health J 2021; 5(1): 4-11.
[http://dx.doi.org/10.1016/j.glohj.2021.02.001] [PMID: 33585050]
[4]
Liu P, Niu R, Chen J, et al. Epidemiological and clinical features in patients with coronavirus disease 2019 outside of Wuhan, China: Special focus in asymptomatic patients. PLoS Negl Trop Dis 2021; 15(3): e0009248.
[http://dx.doi.org/10.1371/journal.pntd.0009248] [PMID: 33690662]
[5]
Abbasi Z, Saghari S, Nashtifani AH, Daneshi S, Hushmandi K, Raesi R. Frequency distribution of depression and its associated factors among pregnant women during the COVID-19 pandemic. Open Public Health J 2023; 16(1): e18749445252830.
[http://dx.doi.org/10.2174/0118749445252830231026060947]
[6]
Danesh F, Ghavidel S. Coronavirus: Scientometrics of 50 years of global scientific productions. Iran J Med Microbiol 2020; 14(1): 1-16.
[http://dx.doi.org/10.30699/ijmm.14.1.1]
[7]
Faryabi R, Rahimi T, Daneshi S, et al. Stress coping styles in family and relatives of coronavirus disease 2019 (COVID-19) patients in the south of Iran: Application of Lazarus and Folkman’s theory of stress coping. Open Public Health J 2022; 15(1): e187494452209210.
[http://dx.doi.org/10.2174/18749445-v15-e220927-2021-243]
[8]
Askarpour H, Domari AA, Jafarnejad A, Hejazi Fard SN, Hashemi M, Faryabi R. Evaluation of Health-promoting Lifestyles in Iranian students during the COVID-19 Epidemic: An Observational Study. Open Public Health J 2023; 16(1)
[9]
Tavakoli A. Incidence and prevalence of tuberculosis in Iran and neighboring countries. Zahedan J Res Med Sci 2017; 19(7)
[http://dx.doi.org/10.5812/zjrms.9238]
[10]
Merza MA, Farnia P, Salih AM, Masjedi MR, Velayati AA. The most predominant spoligopatterns of Mycobacterium tuberculosis isolates among Iranian, Afghan-immigrant, Pakistani and Turkish tuberculosis patients: A comparative analysis. Chemotherapy 2010; 56(3): 248-57.
[http://dx.doi.org/10.1159/000316846] [PMID: 20551642]
[11]
Jimma W, Ghazisaeedi M, Shahmoradi L, et al. Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: Systematic review and meta-analysis. Rev Soc Bras Med Trop 2017; 50(3): 287-95.
[http://dx.doi.org/10.1590/0037-8682-0002-2017] [PMID: 28700044]
[12]
Bialvaei AZ, Asgharzadeh M, Aghazadeh M, Nourazarian M, Kafil HS. Challenges of tuberculosis in Iran. Jundishapur J Microbiol 2017; 10(3): e15558.
[13]
Raesi R, Bokaie S, Hushmandi K, Raei M. Evaluation of patients’ satisfaction with the diagnosis of COVID-19 from the quality of nursing services in corona ward: A cross-sectional study. J Critic Care Nurs 2022; 15(1): 25-33.
[14]
Chakaya J, Khan M, Ntoumi F, et al. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts. Int J Infect Dis 2021; 113 (Suppl. 1): S7-S12.
[http://dx.doi.org/10.1016/j.ijid.2021.02.107] [PMID: 33716195]
[15]
Sorvor FKB, Ewusie EA. The impact of genexpert MTB/RIF technology on the minimization of tuberculosis: A review of literature. Asian J Med Health 2024; 22(1): 1-12.
[http://dx.doi.org/10.9734/ajmah/2024/v22i1969]
[16]
Mishra A. A Novel Model of "Remedy and Elimination of Tuberculosis" [Master's thesis]. San Francisco, CA: University of San Francisco; 2017. Available from: https://repository.usfca.edu/thes/1118/
[17]
WHO. Tuberculosis control in the South-East Asia region. 2015. Available From: https://iris.who.int/handle/10665/205286
[18]
Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis. Semin Respir Crit Care Med. 2018; 39(3): 271-285.
[http://dx.doi.org/10.1055/s-0038-1651492.]
[19]
Davies PDO. The world-wide increase in tuberculosis: How demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. Ann Med 2003; 35(4): 235-43.
[http://dx.doi.org/10.1080/07853890310005713] [PMID: 12846265]
[20]
Bhargava A, Bhargava M. Tuberculosis deaths are predictable and preventable: Comprehensive assessment and clinical care is the key. J Clin Tuberc Other Mycobact Dis 2020; 19: 100155.
[http://dx.doi.org/10.1016/j.jctube.2020.100155] [PMID: 32211519]
[21]
Bagcchi S. WHO’s global tuberculosis report 2022. Lancet Microbe 2023; 4(1): e20.
[http://dx.doi.org/10.1016/S2666-5247(22)00359-7] [PMID: 36521512]
[22]
Liang C, Yu J, Tang S. Interpretation of the global tuberculosis report 2022 by world health organization. J Diagn Concepts Pract. 2023; 22(1): 21-30.
[http://dx.doi.org/10.16150/j.1671-2870.2023.01.004]
[23]
Suthar AB, Zachariah R, Harries AD. Ending tuberculosis by 2030: Can we do it? Int J Tuberc Lung Dis 2016; 20(9): 1148-54.
[http://dx.doi.org/10.5588/ijtld.16.0142] [PMID: 27510238]
[24]
Petersen E, Blumberg L, Wilson ME, Zumla A. Ending the Global Tuberculosis Epidemic by 2030—The Moscow declaration and achieving a major translational change in delivery of TB healthcare. Int J Infect Dis 2017; 65: 156-8.
[http://dx.doi.org/10.1016/j.ijid.2017.11.029] [PMID: 29203390]
[25]
Harries AD, Lin Y, Kumar AMV, et al. What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? F1000 Res 2018; 7: 1011.
[http://dx.doi.org/10.12688/f1000research.14821.1] [PMID: 30026917]
[26]
Bhargava A, Bhargava M, Juneja A. Social determinants of tuberculosis: Context, framework, and the way forward to ending TB in India. Expert Rev Respir Med 2021; 15(7): 867-83.
[http://dx.doi.org/10.1080/17476348.2021.1832469] [PMID: 33016808]
[27]
Daneshi S, Ebadi Fard Azar F, Ahmadi Tabatabaei SV, et al. Process and outcome evaluation of directly observed treatment short course (DOTs) in Kerman city, Southeast of Iran. Indian J Tuberc 2022; 69(4): 620-5.
[http://dx.doi.org/10.1016/j.ijtb.2021.09.001] [PMID: 36460399]
[28]
Feleke BE, Feleke TE, Biadglegne F. Nutritional status of tuberculosis patients, a comparative cross-sectional study. BMC Pulm Med 2019; 19(1): 182.
[http://dx.doi.org/10.1186/s12890-019-0953-0] [PMID: 31638950]
[29]
Karyadi E, West CE, Nelwan RH, Dolmans WM, Schultink JW, van der Meer JW. Social aspects of patients with pulmonary tuberculosis in Indonesia. Southeast Asian J Trop Med Public Health 2002; 33(2): 338-45.
[PMID: 12236434]
[30]
Hassan Zadeh J, Nasehi M, Rezaianzadeh A, Tabatabaee H, Rajaeifard A, Ghaderi E. Pattern of reported tuberculosis cases in iran 2009-2010. Iran J Public Health 2013; 42(1): 72-8.
[PMID: 23514975]
[31]
Nasehi M, Hassanzadeh J, Rezaianzadeh A, Zeigami B, Tabatabaee H, Ghaderi E. Diagnosis delay in smear positive tuberculosis patients. J Res Med Sci 2012; 17(11): 1001-4.
[32]
Babamahmoodi F, Alikhani A, Yazdani Charati J, Ghovvati A, Ahangarkani F, Delavarian L. Clinical epidemiology and paraclinical findings in tuberculosis patients in north of Iran. Biomed Res Int 2015; 2015(11): 381572.
[http://dx.doi.org/10.1155/2015/381572]
[33]
Yin J, Yuan J, Hu Y, Wei X. Association between directly observed therapy and treatment outcomes in multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One 2016; 11(3): e0150511.
[http://dx.doi.org/10.1371/journal.pone.0150511] [PMID: 26930287]
[34]
Wei X-L, Yin J, Zou G-Y, et al. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. Int J Tuberc Lung Dis 2015; 19(4): 413-9.
[http://dx.doi.org/10.5588/ijtld.14.0485] [PMID: 25859996]
[35]
Sotgiu G, Migliori GB. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther 2015; 32: 144-8.
[http://dx.doi.org/10.1016/j.pupt.2014.04.006] [PMID: 24792579]
[36]
Prasad R. Management of multi-drug resistant tuberculosis: Practitioner’s view point. Indian J Tuberc 2007; 54(1): 3-11.
[PMID: 17455417]
[37]
Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis 2021; 113 (Suppl. 1): S96-9.
[http://dx.doi.org/10.1016/j.ijid.2021.02.067] [PMID: 33713815]
[38]
Zimmer AJ, Heitkamp P, Malar J, et al. Facility-based directly observed therapy (DOT) for tuberculosis during COVID-19: A community perspective. J Clin Tuberc Other Mycobact Dis 2021; 24: 100248.
[http://dx.doi.org/10.1016/j.jctube.2021.100248] [PMID: 34189276]
[39]
Shalahuddin I, Pebrianti S, Eriyani T, Maulana I. Telenursing intervention for pulmonary tuberculosis patients-a scoping review. J Multidiscip Healthc 2024; 17: 57-70.
[http://dx.doi.org/10.2147/JMDH.S440314] [PMID: 38196938]
[40]
Zhang Y, Zhang L, Gao W, et al. The impact of COVID-19 pandemic on reported tuberculosis incidence and mortality in China: An interrupted time series analysis. J Glob Health 2023; 13: 06043.
[http://dx.doi.org/10.7189/jogh.13.06043] [PMID: 37824176]
[41]
Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond) 2020; 52(12): 902-7.
[http://dx.doi.org/10.1080/23744235.2020.1806353] [PMID: 32808838]
[42]
Zhang X, Andersen AB, Lillebaek T, et al. Effect of sex, age, and race on the clinical presentation of tuberculosis: A 15-year population-based study. Am J Trop Med Hyg 2011; 85(2): 285-90.
[http://dx.doi.org/10.4269/ajtmh.2011.10-0630] [PMID: 21813849]
[43]
Zhu M, Han G, Takiff HE, et al. Times series analysis of age-specific tuberculosis at a rapid developing region in China, 2011–2016. Sci Rep 2018; 8(1): 8727.
[http://dx.doi.org/10.1038/s41598-018-27024-w] [PMID: 29880836]
[44]
Marçôa R, Ribeiro A, Zão I, Duarte R. Tuberculosis and gender- Factors influencing the risk of tuberculosis among men and women by age group. Pulmonol J 2018; 24(3): 199-202.
[45]
Hagiya H, Koyama T, Zamami Y, et al. Trends in incidence and mortality of tuberculosis in Japan: A population-based study, 1997–2016. Epidemiol Infect 2019; 147: e38.
[http://dx.doi.org/10.1017/S095026881800290X] [PMID: 30409242]
[46]
Dodd PJ, Sismanidis C, Glaziou P. Methods for estimating tuberculosis incidence and mortality by age and sex. Int J Epidemiol 2021; 50(2): 570-7.
[http://dx.doi.org/10.1093/ije/dyaa257] [PMID: 33624797]
[47]
Sepehr MM, Fouladvand F, Mirzaei M. Evaluation of incidence and TB treatment success rates in yazd province (2005-2014). J Shahid Sadoughi Univ Med Sci 2019; 27(8): 1804-13.
[48]
Iliyasu Z, Babashani M. Prevalence and predictors of tuberculosis coinfection among HIV-seropositive patients attending the Aminu Kano Teaching Hospital, northern Nigeria. J Epidemiol 2009; 19(2): 81-7.
[http://dx.doi.org/10.2188/jea.JE20080026] [PMID: 19265273]
[49]
Shah NS, Cavanaugh JS, Pratt R, et al. Epidemiology of smear-negative pulmonary tuberculosis in the United States, 1993–2008. Int J Tuberc Lung Dis 2012; 16(9): 1234-40.
[http://dx.doi.org/10.5588/ijtld.11.0794] [PMID: 22748057]
[50]
Rai D, Kirti R, Kumar S, Karmakar S, Thakur S. Radiological difference between new sputum-positive and sputum-negative pulmonary tuberculosis. J Family Med Prim Care 2019; 8(9): 2810-3.
[http://dx.doi.org/10.4103/jfmpc.jfmpc_652_19] [PMID: 31681647]
[51]
Daneshi S, Naghibzadeh-Tahami A, Razaghi AR, Sheikhshoaei M, Rezabeigi Davarani E. Epidemiologic study of tuberculosis in Kerman city during 2011 â 2015. Health Devel J 2018; 7(3): 218-26.

Rights & Permissions Print Cite
© 2026 Bentham Science Publishers | Privacy Policy